Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 9, 2015, Pages 667-669

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; LIRAGLUTIDE; LIXISENATIDE; SEMAGLUTIDE; TASPOGLUTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART RATE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE;

CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; MALE;

EID: 84940736622     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00256-9     Document Type: Note

References (11)

1. Holman RR, Sourij H, Califf RM Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014, 383:2008-2017.
2. Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011, 2011:215764.
3. Sun F, Yu K, Wu S, et al. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Res Clin Pract 2012, 98:386-395.
4. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obesity Metab 2014, 16:38-47.
5. Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJV Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol 2015, published online Aug 12. http://dx.doi.org/10.1016/S2213-8587(15)00233-8.
6. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011, 10:22.
7. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2:3 liraglutide clinical development studies. Diab Vasc Dis Res 2011, 8:237-240.
8. Wu S, Sun F, Zhang Y, et al. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials. J Clin Pharm Ther 2014, 39:7-13.
9. Seshasai SR, Bennett RL, Petrie JR, et al. Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. Diabetes Obesity Metab 2015, 17:505-510.
10. Pfeffer MA, and members of the ELIXA executive committee. The evaluation of lixisenatide in acute coronary syndrome-the results of ELIXA. Annual Meeting of the American Diabetes Association; Boston, MA, USA; June 5-9, 2015.
11. Scheen AJ, Charbonnel B Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 2014, 40:176-185.